Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer

Expert Opin Investig Drugs. 2021 Aug;30(8):789-795. doi: 10.1080/13543784.2021.1940950. Epub 2021 Jun 21.

Authors

Alicia F C Okines¹, Lara Ulrich¹

Affiliation

¹ Department of Breast Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UK.

PMID: 34114911
DOI: 10.1080/13543784.2021.1940950

No abstract available

Keywords: ADCs; Antibody-drug conjugates; HER2+ breast cancer; breast cancer; bystander killing; linker; payload; triple negative breast cancer.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / pharmacology*
Breast Neoplasms / drug therapy*
Breast Neoplasms / immunology
Drugs, Investigational / administration & dosage
Drugs, Investigational / pharmacology
Female
Humans
Immunoconjugates / administration & dosage
Immunoconjugates / pharmacology*

Substances

Antineoplastic Agents, Immunological
Drugs, Investigational
Immunoconjugates